NovaScan, a clinical stage oncology company based in Chicago, announced that it will be presenting a poster at ACG Annual Scientific Meeting, to be held from October 21-26th at the Charlotte Convention Center in Charlotte NC.
NovaScan’s poster will be titled Cole Relaxation Frequency: A Parameter for Cancer Detection. The poster will discuss the results of a recent study involving assessment of pancreatic tissue with NovaScan’s technology. The poster sessions at ACG will be held from 10:00 am – 12:00 pm on October 25th.
“We are excited about the potential for our technology in GI” remarked NovaScan CEO Craig Davis. “Minimally invasive detection of pancreatic cancer can be challenging. Through the use of our electrical technology, we believe that we can make this easier and simpler for clinicians. Pancreatic cancer is often fatal, and early detection is extremely important.”
“The initial NovaScan pancreatic results are extremely exciting.” noted Isaac Raijman, MD. “We will be following these results with a larger ex vivo study at Texas International Endoscopy Center. We think there is tremendous potential for this technology in several areas of GI. We think it will be widely adopted and think it can improve the standard of care in a few areas.”
Based in Chicago, NovaScan is a clinical stage oncology company that has developed and is productizing a platform technology for point of care cancer detection and stratification. NovaScan has compelling in data in skin, lung, breast, and pancreatic cancer. Further information can be found at www.novascaninc.com
This article was originally published on NovaScanInc.com.